Axogen Inc vs Ryanair Holdings plc — how do they compare? Axogen Inc trades at $39.4 (market cap $2.06B), while Ryanair Holdings plc trades at $64.3 (market cap $31.19B). The key difference: Ryanair Holdings plc is far larger — about 15.1× Axogen Inc's market cap, and Ryanair Holdings plc pays a 1.54% dividend while Axogen Inc pays none. Which is the better fit depends on your goals.
| AXGN | RYAAY | |
|---|---|---|
Market Cap | $2.06B | $31.19B |
Sector | Technology | Industrials |
52-Week High | $46.19 | $73.82 |
52-Week Low | $11.28 | $53.24 |
Enterprise Value | $1.98B | $28.85B |
Dividend Yield | — | 1.54% |
Signals from Pluang's Aura AI — not financial advice
AXGN trades at $39.49, down 2.69% today, with a bearish technical signal despite recent earnings volatility. The company reported mixed quarterly results with Q3 2025 beating estimates but Q1 2026 missing expectations. Strong analyst sentiment persists with 84% buy ratings and a $47.60 consensus price target, though negative profit margins and recent technical weakness create uncertainty.
The outlook remains cautiously optimistic given strong institutional support and reimbursement progress, but investors face risks from persistent losses and competitive pressures. The stock's current position near support at $39 suggests potential for recovery if upcoming Q2 earnings meet or exceed the $0.09 EPS estimate.
RYAAY trades at $63.91, down 1.14% today, with a bullish technical signal from moving averages and neutral oscillators. The company shows strong profitability with a 13.98% net income margin and 25.37% ROE, supported by consistent earnings beats in recent quarters. Recent news includes a window incident investigation and CEO contract extension, while passenger traffic grew 7% year-over-year in June 2026 (Zacks Investment Research, 2026-07-02).
The outlook remains positive with analyst consensus at 62.5% buy ratings, though risks include rising fuel costs and regulatory scrutiny. Valuation appears reasonable with a P/E of 13.74 and EV/EBITDA of 6.57, suggesting potential upside if travel demand sustains. Near-term focus is on Q2 2026 earnings against expectations of $1.37 EPS.
Trailing returns across standard periods
Latest headlines on both assets
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →